OR-NIKE
11.3.2019 17:43:09 CET | Business Wire | Press release
Today, more than 28 of the world’s top female footballers joined Nike (NYSE:NKE) in Paris to unveil 14 National Team Collections for this summer’s tournament in France. Record-breaking gymnast Simone Biles, champion fencer Ibtihaj Muhammad, two-time Grand Slam winner Li Na and other elite athletes also joined Nike in highlighting new partnerships to champion women and girls in sport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190311005652/en/
“We believe this summer can be another turning point for the growth of women’s football,” said NIKE, Inc. Chairman, President and CEO Mark Parker. “And our bigger ambition is for that energy and participation to extend into all sports. Nike’s commitment is to continue our leading support of competitive athletes, invest in the next generation at the grassroots level and deliver more innovative and compelling product design for women.”
At the historic Palais Brongniart, Nike revealed an array of future-forward women’s innovation. Design for the 14 National Team Kits began with gathering detailed input on fit from professional footballers, followed by 4D scanning and motion capture in the Nike Sports Research Lab. Echoing this focus on women’s-specific precision engineering is Nike’s Spring/Summer 2019 high-performance bra collection, which was also on display at the event. Beyond innovations in fit, the National Team Kits reflect Nike’s continued commitment to being the world’s most sustainable sports brand, with each 2019 Nike Kit constructed from at least 12 recycled plastic bottles. Since 2010, Nike has diverted more than 6 billion plastic bottles from landfills through sustainable product design.
At the event, Nike also announced a new three-year partnership with UEFA Women’s Football, building on its support of elite footballers from North America to China, and its support of standout female athletes worldwide. In basketball, Nike is partnering with the WNBA, FIBA and the Chinese Basketball Association to grow the women’s game. Meanwhile, at the collegiate level, Nike is partnering with more than 200 universities across the U.S. to support more than 25,000 top female athletes across multiple sports.
At the grassroots level, Nike is addressing barriers to girls’ participation in sport through new community partnerships and access to products to help girls play with confidence. In Paris, Nike is partnering with Sport dans la Ville to train female coaches and engage girls through sports ranging from football and boxing to tennis and dance. Globally, Nike is collaborating with Women Win and Gurls Talk to support rising female coaches who are inspiring the next generation of girls to be active. And from London to Los Angeles, and Beijing to Buenos Aires, Nike is piloting a program to provide products such as the Nike Pro Hijab and Nike Classic Sports Bra to girls in need through schools and community partners worldwide.
Inspiration for these partnerships comes from female athletes who embody strength, power, and the heart and soul of Nike. Throughout 2019, Nike will honor female champions and changemakers with the next phase of its “Just Do It” campaign, which has inspired millions of athletes to chase their crazy dreams. This year, Nike’s campaign shines a spotlight on women around the world who have broken barriers, revolutionized sport and helped level the playing field for all. Click here to view the newest chapters in Nike’s “Just Do It” film series, launching this year in key cities across the globe.
NIKE, Inc., based near Beaverton, Ore., is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Wholly-owned NIKE, Inc. subsidiary brands include Converse, which designs, markets and distributes athletic lifestyle footwear, apparel and accessories; and Hurley, which designs, markets and distributes surf and youth lifestyle footwear, apparel and accessories. For more information, Nike’s earnings releases and other financial information are available at http://investors.nike.com . Individuals can also visit http://news.nike.com and follow @Nike.
For more information, including multi-media materials, please visit: http://news.nike.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20190311005652/en/
Contact:
Media Contact Mark Rhodes (503) 532-8877
Investor Contact Nitesh Sharan (503) 532-2828
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
